This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsueh, P.-R.
Right arrow Articles by Luh, K.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsueh, P.-R.
Right arrow Articles by Luh, K.-T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 512-517, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.512-517.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003

Po-Ren Hsueh,1* Yeu-Jun Lau,2 Yin-Ching Chuang,3 Jen-Hsien Wan,4 Wen-Kuei Huang,5 Jainn-Ming Shyr,2 Jing-Jou Yan,6 Kwok-Woon Yu,7 Jiunn-Jong Wu,6 Wen-Chien Ko,6 Yi-Chueh Yang,3 Yung-Ching Liu,4 Lee-Jene Teng,1 Cheng-Yi Liu,7 and Kwen-Tay Luh1

Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine,1 Taipei Veterans General Hospital, Taipei,7 Taichung Veterans General Hospital,2 China Medical College Hospital, Taichung,4 Chi-Mei Medical Center,3 National Cheng-Kung University Hospital, Tainan,6 Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan5

Received 5 August 2004/ Accepted 26 September 2004

The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 µg/ml, and for all other Candida species isolates, voriconazole MICs were ≤0.5 µg/ml. The proportions of isolates for which amphotericin B MICs were ≥2 µg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were ≥16 µg/ml, and two (3%) isolates were not inhibited by 1 µg of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 µg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 µg/ml) and 90% (2 µg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by ≤1 µg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

* Corresponding author. Mailing address for Po-Ren Hsueh: Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Rd., Taipei 100, Taiwan. Phone: 886-2-23123456, ext. 5363. Fax: 886-2-23224263. E-mail: hsporen{at}ha.mc.ntu.edu.tw. Mailing address for Cheng-Yi Liu: Department of Internal Medicine, Veterans General Hospital-Taipei, Taipei, Taiwan. Phone: 886-2-28757494. Fax: 886-2-28730052.

Antimicrobial Agents and Chemotherapy, February 2005, p. 512-517, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.512-517.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., Diekema, D. J. (2009). Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007. J. Clin. Microbiol. 47: 3185-3190 [Abstract] [Full Text]  
  • Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C. (2009). Efflux-Mediated Antifungal Drug Resistance. Clin. Microbiol. Rev. 22: 291-321 [Abstract] [Full Text]  
  • Ruan, S.-Y., Chu, C.-C., Hsueh, P.-R. (2008). In Vitro Susceptibilities of Invasive Isolates of Candida Species: Rapid Increase in Rates of Fluconazole Susceptible-Dose Dependent Candida glabrata Isolates. Antimicrob. Agents Chemother. 52: 2919-2922 [Abstract] [Full Text]  
  • Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., Denning, D. W. (2007). Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153: 1677-1692 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Sheehan, D. J. (2006). Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clin. Microbiol. Rev. 19: 435-447 [Abstract] [Full Text]  
  • Vandeputte, P., Larcher, G., Berges, T., Renier, G., Chabasse, D., Bouchara, J.-P. (2005). Mechanisms of Azole Resistance in a Clinical Isolate of Candida tropicalis. Antimicrob. Agents Chemother. 49: 4608-4615 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»